Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137


Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.

Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, Dinsart C, Herrmann A, Balboni G, Rommelaere J, Raykov Z.

Clin Cancer Res. 2009 Jan 15;15(2):511-9. doi: 10.1158/1078-0432.CCR-08-1088.


Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.

Grekova SP, Aprahamian M, Daeffler L, Leuchs B, Angelova A, Giese T, Galabov A, Heller A, Giese NA, Rommelaere J, Raykov Z.

Cancer Biol Ther. 2011 Nov 15;12(10):888-95. doi: 10.4161/cbt.12.10.17678. Epub 2011 Nov 15.


Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer.

Watanabe I, Kasuya H, Nomura N, Shikano T, Shirota T, Kanazumi N, Takeda S, Nomoto S, Sugimoto H, Nakao A.

Cancer Chemother Pharmacol. 2008 Apr;61(5):875-82. Epub 2007 Aug 29.


Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.

Li J, Bonifati S, Hristov G, Marttila T, Valmary-Degano S, Stanzel S, Schnölzer M, Mougin C, Aprahamian M, Grekova SP, Raykov Z, Rommelaere J, Marchini A.

EMBO Mol Med. 2013 Oct;5(10):1537-55. doi: 10.1002/emmm.201302796. Epub 2013 Sep 17.


Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.

Angelova AL, Grekova SP, Heller A, Kuhlmann O, Soyka E, Giese T, Aprahamian M, Bour G, Rüffer S, Cziepluch C, Daeffler L, Rommelaere J, Werner J, Raykov Z, Giese NA.

J Virol. 2014 May;88(10):5263-76. doi: 10.1128/JVI.03688-13. Epub 2014 Feb 26.


Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.

Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R.

Clin Cancer Res. 2000 May;6(5):1936-48.


Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer.

Graeser R, Bornmann C, Esser N, Ziroli V, Jantscheff P, Unger C, Hopt UT, Schaechtele C, von Dobschuetz E, Massing U.

Pancreas. 2009 Apr;38(3):330-7. doi: 10.1097/MPA.0b013e31819436e6.


Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.

Raykov Z, Grekova S, Galabov AS, Balboni G, Koch U, Aprahamian M, Rommelaere J.

Oncol Rep. 2007 Jun;17(6):1493-9.


Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.

Moehler M, Sieben M, Roth S, Springsguth F, Leuchs B, Zeidler M, Dinsart C, Rommelaere J, Galle PR.

BMC Cancer. 2011 Oct 26;11:464. doi: 10.1186/1471-2407-11-464.


Anticancer effects of an oncolytic parvovirus combined with non-conventional therapeutics on pancreatic carcinoma cell lines.

Raykov Z, Georgieva PB, Angelova A, Galabov AS, Rommelaere J.

Acta Virol. 2009;53(1):57-60.


Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.

Grekova S, Aprahamian M, Giese N, Schmitt S, Giese T, Falk CS, Daeffler L, Cziepluch C, Rommelaere J, Raykov Z.

Cancer Biol Ther. 2010 Dec 15;10(12):1280-9. Epub 2010 Dec 15.


Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.

Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH.

Cancer Res. 2005 Oct 1;65(19):9064-72.


Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.

Zagon IS, Jaglowski JR, Verderame MF, Smith JP, Leure-Dupree AE, McLaughlin PJ.

Cancer Chemother Pharmacol. 2005 Nov;56(5):510-20. Epub 2005 Jun 10.


[In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma].

Kreil A, Bauer J, Scheithauer W.

Acta Med Austriaca. 1999;26(3):93-100. German.


Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.

Damaraju VL, Bouffard DY, Wong CK, Clarke ML, Mackey JR, Leblond L, Cass CE, Grey M, Gourdeau H.

BMC Cancer. 2007 Jul 3;7:121.


Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival.

Ogura Y, Mizumoto K, Nagai E, Murakami M, Inadome N, Saimura M, Matsumoto K, Nakamura T, Maemondo M, Nukiwa T, Tanaka M.

Cancer Gene Ther. 2006 May;13(5):520-9.


Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.

Tang K, Zhang Z, Bai Z, Ma X, Guo W, Wang Y.

Oncol Rep. 2011 Apr;25(4):963-70. doi: 10.3892/or.2011.1139. Epub 2011 Jan 11.


[Establish a gemcitabine-resistant pancreatic cancer cell line SW1990/GZ and research the relationship between SW1990/GZ and pancreatic cancer stem cell].

An Y, Yao J, Wei JS, Lu ZP, Cai HH, Dai CC, Qian ZY, Xu ZK, Miao Y.

Zhonghua Wai Ke Za Zhi. 2010 Jul 1;48(13):999-1003. Chinese.


[Role of nuclear factor-kappaB on emodin-induced sensitization of pancreatic cancer to gemcitabine].

Liu A, Hu YS, Wang ZH, Tang LL, Ke PY, Lin SZ.

Yao Xue Xue Bao. 2011 Feb;46(2):146-52. Chinese.


Supplemental Content

Support Center